US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ready Capital Corp

24.45

-0.0150-0.06%

Volume:6.90K

Turnover:168.83K

Market Cap:- -

PE:- -

High:24.53

Open:24.42

Low:24.42

Close:24.47

Loading ...

Overview Company News Filings

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Europe Approves Merck's Cancer Drug For Two Indications

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Promising Potential of Trevi Therapeutics’ Haduvio in IPF Cough Drives Buy Rating Amid RCC Challenges

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

Rezolve AI Limited (RZLV): Driving AI Innovations in Retail

Junshi Biosciences Announces Toripalimab’s Approval in Australia

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

Royal Caviar Club Partners with Rezolve Ai to Elevate Digital Channels with Conversational Commerce

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RCC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCC\",,,,,undefined,":{"symbol":"RCC","market":"US","secType":"STK","nameCN":"Ready Capital Corp","latestPrice":24.45,"timestamp":1750276800000,"preClose":24.465,"halted":0,"volume":6904,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Post-Mkt","change":-0.015,"latestTime":"06-18 19:26:15 EDT","open":24.42,"high":24.5261,"low":24.42,"amount":168829.8018,"amplitude":0.004337,"askPrice":26.84,"askSize":100,"bidPrice":21.65,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1750291200000},"marketStatusCode":4,"adr":0,"exchange":"NYSE","adjPreClose":24.465,"dividendRate":0.058794,"volumeRatio":3.122851},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCC\",,,,,undefined,":{"symbol":"RCC","floatShares":0,"roa":"-2.31%","roe":"-11.15%","lyrEps":0,"volumeRatio":3.122851,"shares":0,"dividePrice":1.43752,"high":24.5261,"amplitude":0.004337,"preClose":24.465,"low":24.42,"week52Low":23.85,"pbRate":"0.00","psRate":"0.00","week52High":26.87,"institutionHeld":0,"latestPrice":24.45,"eps":0,"divideRate":0.058794,"volume":6904,"delay":0,"ttmEps":0,"open":24.42,"prevYearClose":24.42,"prevWeekClose":24.38,"prevMonthClose":23.97,"prevQuarterClose":24.75,"fiveDayClose":24.39,"twentyDayClose":24.5,"sixtyDayClose":24.65},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518249238","title":"Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough","url":"https://stock-news.laohu8.com/highlight/detail?id=2518249238","media":"PR Newswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518249238?lang=en_us&edition=fundamental","pubTime":"2025-03-10 04:00","pubTimestamp":1741550400,"startTime":"0","endTime":"0","summary":"Conference call and webcast to be held at 8:30 a.m. ET. NEW HAVEN, Conn., March 9, 2025 /PRNewswire/ --Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis  and refractory chronic cough , today announced a conference call and live webcast taking place tomorrow, Monday, March 10th, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2a RIVER trial of Haduvio in patients with refractory chronic cough.Chronic cough is highly prevalent in IPF patients, impacting up to 85% of the IPF population. There are ~140,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/trevi-therapeutics-host-conference-call-200000325.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trevi-therapeutics-host-conference-call-200000325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","TRVI","LENZ","RCC","BK4139","BK4007","BK4585","BK4181","HST","BK4588"],"gpt_icon":0},{"id":"2517438854","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438854","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438854?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348740,"startTime":"0","endTime":"0","summary":"Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib. PRINCETON, N.J., March 07, 2025----Bristol Myers Squibb  today announced that the European Commission  has approved Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .\"The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma,\" said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. \"This approval marks a critical milestone in our commitment to improving outcomes for patients with liver cancer. We look forward to bringing this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-115900243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1261432733.SGD","LU1670711040.USD","BK4532","LU1571399168.USD","LU2125154935.USD","EC","LU2242646821.SGD","LU1032466523.USD","LU1670710588.SGD","IE00B19Z4B17.USD","BK4132","MYE","OS","LU0321505439.SGD","TEN","HCC","RCC","BK4201","AEIS","LU0306807586.USD","IE00BFTCPJ56.SGD","VOD","ORR","BK4581","LU0225284248.USD","LU0114720955.EUR","LU1868836914.USD","LU0306806265.USD","LU1868837136.USD","LU0096364046.USD","LU1291159041.SGD","IE00B7SZL793.SGD","BMY","LU0237698245.USD","ALK","HSCT","LU0321505868.SGD","BK4213","LU1430594728.SGD","BK4157","LU1868836591.USD","BK4124","BK4097","LU0868494617.USD","CRC","LU1868837300.USD","IE00BSNM7G36.USD","CRT","LU0061475181.USD"],"gpt_icon":0},{"id":"2514801863","title":"Trevi Therapeutics to Participate in Upcoming March Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514801863","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514801863?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:30","pubTimestamp":1740659400,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., Feb. 27, 2025 /PRNewswire/ --Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis  and refractory chronic cough ,today announced that senior management will be attending the following investor conferences in March.Refractory chronic cough affects approximately 2-3 million adults in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly disruptive disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. There are also no approved therapies for RCC in the U.S.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/trevi-therapeutics-participate-upcoming-march-123000073.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trevi-therapeutics-participate-upcoming-march-123000073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TRVI","BK4007","RCC","LENZ","BK4139"],"gpt_icon":0},{"id":"2514095044","title":"Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough","url":"https://stock-news.laohu8.com/highlight/detail?id=2514095044","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514095044?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:30","pubTimestamp":1740486600,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis  and refractory chronic cough , today announced that it has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF. Topline results continue to be expected in the first half of 2025.About Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ex","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/trevi-therapeutics-completes-enrollment-phase-123000676.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trevi-therapeutics-completes-enrollment-phase-123000676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","RCC","BK4007","TRVI"],"gpt_icon":0},{"id":"2514509829","title":"FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2514509829","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514509829?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:45","pubTimestamp":1740483900,"startTime":"0","endTime":"0","summary":"Acceptance based on results from the KEYNOTE-689 trial: the first Phase 3 trial to demonstrate significant improvement in event-free survival in the neoadjuvant and adjuvant setting for an anti-PD-1 therapy in earlier stages of head and neck squamous cell carcinoma. RAHWAY, N.J., February 25, 2025----Merck , known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration  has accepted for priority review a new supplemental Biologics License Application  seeking approval for KEYTRUDA , Merck’s anti-PD-1 therapy, for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma  as neoadjuvant treatment, then continued as adjuvant treatment in combination with standard of care radiotherapy with or without cisplatin and then as a single agent. The FDA has set a Prescription Drug User Fee Act , or target action, date of June 23, 2025.KEYTRUDA is currently approved as monotherapy and in combination regimens for a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-grants-priority-review-merck-114500312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DM","LU0965509101.SGD","LU2106854487.HKD","ALT","LU2468319806.SGD","BTC","CPS","SG9999013999.USD","LU0320765646.SGD","LU1291159041.SGD","LU0006306889.USD","LU1989771016.USD","MRK","HCC","LU1989772923.USD","LU1116320737.USD","LU2361045086.USD","IE00BLSP4239.USD","BK4139","CRC","LU0265550946.USD","IE00BBT3K403.USD","LU2089984988.USD","LU0456854461.SGD","LU1066051225.USD","LU1878469433.USD","BK4534","LU2023250504.SGD","LU0122379950.USD","LU0238689110.USD","RCC","SG9999002224.SGD","LU1929549753.HKD","BCG","HSCT","LU0265550359.USD","LU1585245621.USD","SMP","LU1066053197.SGD","LU0861579265.USD","SG9999015358.SGD","LU1037948541.HKD","LU1093756325.SGD","BK4585","IE00B1BXHZ80.USD","BK4533","CRT","AEIS","LU1066051498.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2513051728","title":"U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...","url":"https://stock-news.laohu8.com/highlight/detail?id=2513051728","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513051728?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:59","pubTimestamp":1740398340,"startTime":"0","endTime":"0","summary":"Application based on analyses from the Phase 3 CheckMate -8HW clinical trial, in which Opdivo plus Yervoy demonstrated superior progression-free survival compared to Opdivo monotherapy and investigator’s choice of chemotherapy. The U.S. Food and Drug Administration assigned a target action date of June 23, 2025. U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer. Opdivo plus Yervoy received approval from the U.S. FDA in July 2018 for the treatment of adult and pediatric patients 12 years and older with MSI-H or dMMR mCRC that have progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan. Opdivo plus Yervoy was also approved in December 2024 in the European Union for the first-line treatment of adult patients with MSI-H or dMMR unresectable or mCRC and in October","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","BK4195","LU0096364046.USD","LU2133065610.SGD","LU1868837136.USD","LU1291159041.SGD","LU1670710588.SGD","LU2242646821.SGD","LU0985481810.HKD","BK4124","LU1323610961.USD","RCC","LU1585245621.USD","LU0266512127.USD","LU1261432733.SGD","LU1868836757.USD","LU1074936037.SGD","LU1670711123.USD","LU2125154778.USD","LU0061475181.USD","IE00BJT1NW94.SGD","BK4559","BK4144","HCC","VOD","LU0882574055.USD","PFS","IE0009355771.USD","BK4008","LU0868494617.USD","CRT","LU2360032135.SGD","IE00B2B36J28.USD","BMY","LU1093756168.USD","LU2242652126.USD","CRC","LU1032466523.USD","ALK","BK4534","BK4585","IE0002141913.USD","BK4211","LU1868836591.USD","TEN","BK4532","MYE","HSCT","BK4126","BK4581"],"gpt_icon":0},{"id":"2513754954","title":"Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2513754954","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513754954?lang=en_us&edition=fundamental","pubTime":"2025-02-24 02:16","pubTimestamp":1740334566,"startTime":"0","endTime":"0","summary":"We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Exelixis, Inc.  stands against other Renaissance Technologies portfolio's top stock picks.The American quant hedge fundRenaissance Technologiesis known for using statistical and mathematical tools to drive its investment programs. It was founded in 1982 by Jim Simons, a mathematician who worked as a code breaker for the US National Security Agency during the Cold War. As of December 31, Renaissance Technologies had a portfolio valued at over $67.5 billion.READ ALSO:Cathie Wood’s Stock Portfolio: 2025 Stock PicksandJim Cramer’s February Portfolio: Top 10 Stocks.We scanned Renaissance Technologies’ 13F portfolio, as of December 31, 2024. From there, we picked the top 10 stocks according to their stake value and ranked them in ascending order.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-inc-exel-among-renaissance-181606873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","TQQQ","NQmain","SQQQ","BK4532","EXEL","USJW.SI",".IXIC","USAW.SI","QLD","PSQ","BK4139","NVIW.SI","RCC","TSYW.SI","MNQmain"],"gpt_icon":1},{"id":"2513219393","title":"Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2513219393","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513219393?lang=en_us&edition=fundamental","pubTime":"2025-02-22 02:30","pubTimestamp":1740162643,"startTime":"0","endTime":"0","summary":"On Friday, Exelixis, Inc. authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025.Exelixis plans to complete the $500 million stock repurchase program, announced in August 2024, in the second quarter of 2025 and commence stock repurchases under the newly authorized stock repurchase program thereafter.As of the end of fiscal year 2024, Exelixis has returned over $1.2 billion to shareholders through these programs.Earlier this month, Exelixis reported fourth-quarter adjusted EPS of 55 cents, beating the consensus of 43 cents. The cancer-focused company reported sales of $566.75 million, beating the consensus of $563.42 million.Recently, Exelixis announced the final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx in combination with Bristol-Myers Squibb & Co’s  Opdivo versus sunitinib for patients with previously untreated advanced renal cell carcinoma .After more than five years of follow-up, the findings ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-cancer-focused-exelixis-stock-183043377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4559","IE00BJT1NW94.SGD","SG9999011175.SGD","LU1032466523.USD","IE0009355771.USD","LU0237698245.USD","BK4534","LU0985481810.HKD","IE000M9KFDE8.USD","LU0225284248.USD","IE00B2B36J28.USD","BK4585","LU0289739699.SGD","LU1057294990.SGD","LU1868837136.USD","PFE","LU1670711040.USD","LU1868836757.USD","EXEL","BK4007","LU1066051498.USD","LU1868837300.USD","LU1261432733.SGD","LU1323610961.USD","LU1670711123.USD","LU1093756325.SGD","SG9999001176.USD","LU2242646821.SGD","LU0306806265.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU1074936037.SGD","BK4599","LU0868494617.USD","LU1883839398.USD","BK4139","LU0882574055.USD","SG9999003800.SGD","LU1585245621.USD","LU1868836591.USD","SG9999002224.SGD","LU0096364046.USD","LU2242652126.USD","BK4533","LU1989771016.USD","LU0306807586.USD","IE00BLSP4452.SGD","BMY","IE00B19Z3B42.SGD","RCC"],"gpt_icon":1},{"id":"2512160948","title":"Europe Approves Merck's Cancer Drug For Two Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2512160948","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512160948?lang=en_us&edition=fundamental","pubTime":"2025-02-19 01:00","pubTimestamp":1739898040,"startTime":"0","endTime":"0","summary":"On Tuesday, the European Commission  conditionally approved Merck& Co Inc’s  Welireg, an oral hypoxia-inducible factor-2 alpha  inhibitor, as monotherapy for:. Adult patients with von Hippel-Lindau  disease who require therapy for associated, localized renal cell carcinoma , central nervous system  hemangioblastomas, or pancreatic neuroendocrine tumors , and for whom localized procedures are unsuitable;Adult patients with advanced clear cell RCC that progressed following two or more lines of therapy.The approval of these two indications is based on results from the LITESPARK-004 and LITESPARK-005 trials, respectively.Also Read: Analysts Defend Merck Amid Investor Concerns Over Weak Guidance. This marks Welireg’s first approval in the European Union . Welireg is now approved in over 30 countries for certain adult patients with previously treated advanced RCC and in more than 40 countries for adult patients with certain eligible VHL disease-associated tumors.The FDA approved Welireg in A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/europe-approves-mercks-cancer-drug-170040277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRK","CNS","SG9999014542.SGD","LU1093756168.USD","LU1989772923.USD","LU0211331839.USD","LU2461242641.AUD","IE00BLSP4452.SGD","LU1934455194.USD","LU0070302665.USD","IE00BSNM7G36.USD","EC","LU0058720904.USD","LU0289739699.SGD","LU1941712348.USD","LU0106261372.USD","LU0965509101.SGD","LU1934455863.HKD","SG9999002224.SGD","BK4585","LU1116320737.USD","LU1929549753.HKD","RCC","LU2361045086.USD","LU0266013472.USD","IE00BJT1NW94.SGD","IE00BN8TJ469.HKD","IE00B2B36J28.USD","SG9999002232.USD","LU0985320562.USD","SGXZ57979304.SGD","LU1291159041.SGD","SG9999014575.USD","LU1430594728.SGD","LU1066051225.USD","LU1162221912.USD","IE0009355771.USD","LU1917777945.USD","LU1116320901.HKD","LU1989771016.USD","LU1989772840.SGD","LU2361044865.SGD","IE00BFTCPJ56.SGD","LU0320765489.SGD","BK4007","IE00BBT3K403.USD","LU1037948541.HKD","LU0203347892.USD","LU0965509283.SGD"],"gpt_icon":0},{"id":"2505498817","title":"Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505498817","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505498817?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:00","pubTimestamp":1737547200,"startTime":"0","endTime":"0","summary":"– Antitumor activity was observed across both viral and non-viral etiologies –。– Data support continued evaluation of casdozokitug with VEGF and PD-1 blockade in HCC –。REDWOOD CITY, Calif., Jan. 22, 2025  -- Coherus BioSciences, Inc., today announced final data from its Phase 2 open label clinical trial evaluating casdozokitug , a selective and potent Interleukin -27-targeting antibody, in combination with atezolizumab  and bevacizumab  in treatment nave patients with unresectable locally advanced or metastatic hepatocellular carcinoma . These data are being presented at the 2025 ASCO Gastrointestinal Cancers Symposium taking place January 23-25, 2025, in San Francisco, California.“The treatment landscape for liver cancer, particularly for patients who are not eligible for surgery or who are metastatic, has improved in recent years thanks to immunotherapy combinations. However, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coherus-presents-final-phase-2-120000655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AE","BK4107","HCC","RCC","BK4585","LU0053666078.USD","BK4161","BK4535","BK4195","CHRS","PFS","BK4138","SEER","BK4211","BK4121","L","BK4588","BK4006","BK4139","CR"],"gpt_icon":0},{"id":"2505574507","title":"Promising Potential of Trevi Therapeutics’ Haduvio in IPF Cough Drives Buy Rating Amid RCC Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2505574507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505574507?lang=en_us&edition=fundamental","pubTime":"2025-01-22 11:25","pubTimestamp":1737516335,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Faisal Khurshid from Leerink Partners maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-potential-of-trevi-therapeutics-haduvio-in-ipf-cough-drives-buy-rating-amid-rcc-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-potential-of-trevi-therapeutics-haduvio-in-ipf-cough-drives-buy-rating-amid-rcc-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RCC","LENZ"],"gpt_icon":0},{"id":"2504340532","title":"Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2504340532","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504340532?lang=en_us&edition=fundamental","pubTime":"2025-01-20 19:12","pubTimestamp":1737371520,"startTime":"0","endTime":"0","summary":"SHANGHAI, Jan.  20, 2025  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/20/3011970/0/en/Junshi-Biosciences-Announces-Commercialization-Partnership-with-LEO-Pharma-for-Toripalimab-in-Europe.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEO","RCC","BK4201","BK4156","EEA","EC"],"gpt_icon":0},{"id":"2504711338","title":"Rezolve AI Limited (RZLV): Driving AI Innovations in Retail","url":"https://stock-news.laohu8.com/highlight/detail?id=2504711338","media":"Insider Monkey","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504711338?lang=en_us&edition=fundamental","pubTime":"2025-01-18 03:04","pubTimestamp":1737140674,"startTime":"0","endTime":"0","summary":"We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going to take a look at where Rezolve AI Limited  stands against other AI companies under $2 billion market cap.It’s clear that AI holds immense promise but it comes with significant risks. Some of the concerns that the market has include overreliance on a few key players, shifts in demand toward smaller competitors, and the broader impact of AI-driven market trends on earnings and valuations. While AI offers opportunities, managing risks such as customer concentration, economic headwinds, and market volatility will be crucial for its sustainable growth and integration.Rezolve AI Limited  specializes in AI-driven solutions for commerce and retail, aiming to enhance customer engagement and drive revenue growth. Its BRAiN Suite, which includes BRAiN Commerce, BRAiN Checkout, and BRAiN Assistant, uses AI to deliver personalized,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rezolve-ai-limited-rzlv-driving-190434566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0251131958.USD","LU1261432733.SGD","LU0964807845.USD","LU0742534661.SGD","LU1951200564.SGD","LU0170899867.USD","USAW.SI","NQmain","LU0154236417.USD","RCC","LU0494093205.USD","TSYW.SI","LU0323591593.USD","USJW.SI","LU0251132253.USD","LU1121112475.USD","LU1815333072.USD","LU2362540622.SGD","LU1064131342.USD","LU2430703178.SGD","PSQ","BK4561","LU1267930730.SGD","LU1429558221.USD","LU0683600562.USD","RZLV","QID","BK4550","TQQQ","LU1951198990.SGD","QLD","LU2430703251.USD","SQQQ","LU1917777945.USD","NVIW.SI","IE00B1BXHZ80.USD","RZLVW","LU1116320901.HKD","SGXZ99366536.SGD","LU2602419157.SGD",".IXIC","MNQmain","LU0056508442.USD","LU0061474960.USD","LU0096364046.USD","SGXZ81514606.USD","LU0882574139.USD","GOOGL","LU2362541513.USD"],"gpt_icon":1},{"id":"2504582641","title":"Junshi Biosciences Announces Toripalimab’s Approval in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2504582641","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504582641?lang=en_us&edition=fundamental","pubTime":"2025-01-17 18:56","pubTimestamp":1737111360,"startTime":"0","endTime":"0","summary":"SHANGHAI, Jan.  17, 2025  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/17/3011315/0/en/Junshi-Biosciences-Announces-Toripalimab-s-Approval-in-Australia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161","RCC"],"gpt_icon":0},{"id":"2503950564","title":"5 Biotech Stocks Worth Adding to Your Portfolio in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503950564","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503950564?lang=en_us&edition=fundamental","pubTime":"2025-01-14 23:02","pubTimestamp":1736866920,"startTime":"0","endTime":"0","summary":"The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.M&A activity is likely to accelerate in 2025 with a change in administration and expected deregulation. Pharma and biotech bigwigs always look to bolster their product portfolios and pipelines through collaborations and buyouts. While oncology and immuno-oncology companies have always been acquisition targets, those with obesity drugs in their portfolio/pipeline and gene-editing companies hold great potential. This will put the spotlight on smaller biotech companies with promising candidates in their kitty.Biotech companies like Incyte INCY, BioMarin Pharmaceutical BMRN, E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-biotech-stocks-worth-adding-150200564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EXEL","RCC","SSO","IVV","BK4581","ESmain","IE00B19Z3B42.SGD","SPXU","BMRN","UPRO","BK4139","BK4550","HALO","IE0002270589.USD","INCY","BK4588",".SPX","LU0053671581.USD","IE00B7SZLL34.SGD","VOO","SDS","BK4585","BK4532","OEF","BK4534","BK4566","BK4559","BK4504","OEX","IE00B19Z3581.USD","SPY","BPMC","SH","BK4505"],"gpt_icon":1},{"id":"2503230941","title":"Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2503230941","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503230941?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"–Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways –。–Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 in combination with pembrolizumab anticipated in fourth quarter of 2025 –。– Initiation of Phase 1/2 dose and regimen-finding clinical trial of WTX-330 expected in firstquarter of 2025 –。– Cash guidance provides runway through at least the second quarter of 2026 –。Werewolf continues to evaluate WTX-124 as a monotherapy and in combination with pembrolizumab through the ongoing Phase 1/1b clinical trial evaluating the INDUKINE molecule in multiple solid tumor types. WTX-124 has shown promising monotherapy activity and an improved tolerability profile versus high dose IL-2 in heavily pretreated patients refractory to all standard-of-care therapies, including immune checkpoint i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/werewolf-therapeutics-provides-business-highlights-130000639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCC","BK4080","SITC","HOWL","BK4539","IBD","LENZ","BK4231","BK4139"],"gpt_icon":0},{"id":"2502081025","title":"FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2502081025","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502081025?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:42","pubTimestamp":1736534520,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that the FDA has notified it about an update to its supplemental new drug application  for cabozantinib.In November 2024, the FDA notified the company that the sNDA for cabozantinib for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors  and advanced extra-pancreatic NET  would be discussed at an Oncologic Drugs Advisory Committee  meeting in March 2025.The FDA has now notified the company that its sNDA will no longer be the subject of discussion at the ODAC meeting. The sNDA is under FDA review and has a target action date of April 3, 2025.Exelixis’ shares have gained 53.2% in the past six months against the industry’s decline of 10.1%.In August 2023, the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board unanimously recommended that enrollment in the CABINET trial be stopped and randomized patients be unblinded to therapy with the allowance for crossover from placebo to cabozantini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-updates-exel-previously-scheduled-184200304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B2B36J28.USD","BK4533","LU0006306889.USD","IMCR","LU2089984988.USD","LU1066051811.HKD","LU1037948897.HKD","LU1291159041.SGD","LU1699723380.USD","EXEL","LU2106854487.HKD","LU1989772840.SGD","LU2361045086.USD","LU0965509010.AUD","LU2112291526.USD","BK4585","LU1571399168.USD","LU0320765489.SGD","PFS","IE000M9KFDE8.USD","LU1934455277.USD","BK4139","SG9999002232.USD","SG9999013999.USD","LU1023059063.AUD","LU1057294990.SGD","IE00BJT1NW94.SGD","BK4516","BK4532","SG9999015358.SGD","DTC","SG9999002224.SGD","IE0002141913.USD","MRK","LU0265550946.USD","RCC","BK4211","IE00BJJMRZ35.SGD","LU1061106388.HKD","CSTL","IE0009355771.USD","LU0058720904.USD","SGXZ57979304.SGD","LU0211331839.USD","LU0985320562.USD","IE00B1BXHZ80.USD","SG9999015341.SGD","LU1093756168.USD","LU0208291251.USD","LU1941712264.USD"],"gpt_icon":0},{"id":"2502916078","title":"Royal Caviar Club Partners with Rezolve Ai to Elevate Digital Channels with Conversational Commerce","url":"https://stock-news.laohu8.com/highlight/detail?id=2502916078","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502916078?lang=en_us&edition=fundamental","pubTime":"2025-01-11 00:31","pubTimestamp":1736526660,"startTime":"0","endTime":"0","summary":"AI-Driven Innovation to Redefine Customer Engagement in the Growing $4.19 Billion Caviar MarketNEW YORK and HONG KONG, Jan.  10, 2025  (GLOBE NEWSWIRE) -- Royal Caviar Club (RCC), celebrated as the “B","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/10/3007837/0/en/Royal-Caviar-Club-Partners-with-Rezolve-Ai-to-Elevate-Digital-Channels-with-Conversational-Commerce.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345780281.USD","RCC","BK4585","BK4588","BK4023","RZLV","RGLD","BK4017","LU0345780521.USD"],"gpt_icon":0},{"id":"2501298870","title":"Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501298870","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501298870?lang=en_us&edition=fundamental","pubTime":"2025-01-07 02:26","pubTimestamp":1736187960,"startTime":"0","endTime":"0","summary":"Shares of Exelixis, Inc. EXEL have surged 50% in a year against the industry’s decline of 16.1%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The company's stellar performance can be attributed to the strong growth of its lead drug, Cabometyx, raised guidance and encouraging pipeline progress.Exelixis also intends to submit an sNDA with the FDA for cabozantinib, in combination with Tecentriq , for metastatic castration-resistant prostate cancer.Another promising candidate in Exelixis’ pipeline is zanzalintinib, a next-generation oral TKI. Enrollment has been completed in the late-stage STELLAR-303 study evaluating zanzalintinib, in combination with Tecentriq, compared with regorafenib in patients with metastatic refractory colorectal cancer that is not microsatellite instability-high or mismatch repair-deficient. Preliminary results from the study are expected in 2025.Exelixis recently collaborated with pharma giant Merck MRK to evaluate zanzalinti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-stock-surges-50-room-182600401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1934455277.USD","LU1323610961.USD","LU0965509283.SGD","LU0965509101.SGD","LU0868494617.USD","LU1868837300.USD","LU0265550359.USD","LU0965509010.AUD","SG9999013999.USD","LU0965508806.USD","BK4532","LU1670710661.SGD","LU1941712348.USD","MRK","LU2112291526.USD","LU2106854487.HKD","LU2125154935.USD","SG9999014542.SGD","RCC","LU0208291251.USD","LU1670711040.USD","LU1093756325.SGD","LU1934455863.HKD","IE00BBT3K403.USD","IE0002141913.USD","LU0114720955.EUR","LU0265550946.USD","BMY","SG9999014575.USD","LU1023059063.AUD","SG9999014567.USD","LU1585245621.USD","LU0306806265.USD","LU2242646821.SGD","LU0211331839.USD","LU1868837136.USD","LU1941712264.USD","IE0009355771.USD","LU0321505868.SGD","IE00B4R5TH58.HKD","LU1571399168.USD","LU1989772840.SGD","LU1430594728.SGD","EXEL","BK4139","LU0203345920.USD","LU0106261372.USD","BK4533","SG9999001176.SGD"],"gpt_icon":0},{"id":"2492121011","title":"Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2492121011","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492121011?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:00","pubTimestamp":1734609600,"startTime":"0","endTime":"0","summary":"Company expects to share preliminary Phase 1 clinical data in the first half of 2025. For more information about becoming a study site, please email clinicaltrials@adicetbio.com.ADI-270 is an armored allogeneic \"off-the-shelf\" gamma delta CAR T cell therapy candidate targeting CD70-positive cancers. CD70 is a compelling target due to its high expression in both solid and hematological malignancies. ADI-270 is engineered with a third-generation CAR designed to target CD70 using its natural receptor, CD27, as the binding moiety and is further armored with a dominant negative form of the transforming growth factor-β receptor II  to provide functional resilience to the immunosuppressive tumor microenvironment. ADI-270 is also designed to increase exposure and persistence by reducing susceptibility to host vs. graft eliminati","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/U2gCb0_Nvz2zIIPCmTN9TA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/49f0cf03f173e43dd83ce55b7c3c1a52","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/U2gCb0_Nvz2zIIPCmTN9TA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/49f0cf03f173e43dd83ce55b7c3c1a52"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-bio-announces-first-patient-120000866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1815336760.USD","LU2237443622.USD","LU2298322129.HKD","LU2237443549.SGD","BK4139","LU1642822529.SGD","LU2458330243.SGD","LU1670710588.SGD","IE00B66KJ199.SGD","LU1670710661.SGD","LU0719512351.SGD","LU2237443382.USD","LU1244550577.SGD","LU0124384867.USD","LU2272731782.SGD","RCC","ADI","IE0009356076.USD","LU1074936037.SGD","LU1992135472.HKD","LU0889565833.HKD","LU1670711123.USD","LU1861219969.SGD","BK4585","LU0109392836.USD","LU2360107325.USD","LU1244550221.USD","LU0957808578.USD","BK4588","LU0314104364.USD","LU0082616367.USD","LU1992135399.USD","LU2237438978.USD","LU2272731600.USD","ACET","IE00BD6J9T35.USD","LU1670711040.USD","LU2458330169.SGD","BK4561","BK4515","IE00B7SZL793.SGD","LU0724618433.USD","AEIS","IE00B19Z4B17.USD","LU1861214812.USD","IE00B5949003.HKD","LU1244550494.USD","IE00BZ199S13.USD","BK4157","LU2237443978.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCC\",params:#limit:5,,,undefined,":[{"date":"2025-07-15","symbol":"RCC","amount":0.35938,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-15","defaultRemindTime":1752586200000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-30","payableDate":"2025-07-15","currency":"USD","dateTimestamp":1752552000000,"payDate":"2025-07-30"},{"date":"2025-05-08","symbol":"RCC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1746734400000,"name":null,"time":"Post Market","dateTimestamp":1746676800000,"actualEps":null},{"date":"2025-04-15","symbol":"RCC","amount":0.35938,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-15","defaultRemindTime":1744723800000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-15","currency":"USD","dateTimestamp":1744689600000,"payDate":"2025-04-30"},{"market":"US","date":"2025-03-03","symbol":"RCC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":null},{"date":"2025-01-15","symbol":"RCC","amount":0.35938,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-15","defaultRemindTime":1736951400000,"name":"Ready Capital Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-30","payableDate":"2025-01-15","currency":"USD","dateTimestamp":1736917200000,"payDate":"2025-01-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCC\",market:\"US\",,,undefined,":[{"executeDate":"2021-04-14","recordDate":"2021-04-15","paymentDate":"2021-04-30","value":0.3194444,"currency":"USD"},{"executeDate":"2021-07-14","recordDate":"2021-07-15","paymentDate":"2021-07-30","value":0.359375,"currency":"USD"},{"executeDate":"2021-10-14","recordDate":"2021-10-15","paymentDate":"2021-10-30","value":0.359375,"currency":"USD"},{"executeDate":"2022-01-13","recordDate":"2022-01-14","paymentDate":"2022-01-30","value":0.359375,"currency":"USD"},{"executeDate":"2022-04-13","recordDate":"2022-04-14","paymentDate":"2022-04-30","value":0.359375,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RCC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.875,"sell":0.125,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.875,"analysts":8,"updateTime":1741060800000}}}